Skip to main content

Table 10 Bayesian method estimates of indirect probabilities of passing different visual acuity thresholds at month 1 for patients with CRVO on scale of GENEVA trial

From: Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion

Improvement or worsening at Month 1

Probability for Group§ (95% CrI)

Relative risk (95% CrI)*

 

Ranibizumab

Dexamethasone

 

Gain ≥15 letters

0.185 (0.063,0.366)

0.213 (0.149,0.283)

1.15 (0.47,2.85)

Gain ≥5 letters and <15 letters

0.434 (0.276,0.600)

0.404 (0.325,0.487)

0.93 (0.60,1.44)

Loss <5 letters and gain <5 letters

0.076 (0.037,0.135)

0.298 (0.226,0.376)

3.91 (1.92,7.98)

Loss ≥5 letters and <15 letters

0.286 (0.154,0.451)

0.043 (0.016,0.081)

0.15 (0.06,0.39)

Loss ≥15 letters

0.018 (0.002,0.061)

0.042 (0.016,0.081)

2.30 (0.33,15.85)

  1. §Mean of 100000 samples from posterior distributions of probability for change in BCVA from baseline category.
  2. *Ratio of mean probabilities with credible interval based on Delta method on log scale.
Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us